AAI supports US high court review of case against Merck over mumps vaccines
( August 11, 2025, 22:31 GMT | Official Statement) -- MLex Summary: The American Antitrust Institute told the Supreme Court that it should rule that Merck handicapped a rival, distorted the adjudication process, and denied consumers the benefits of competition by providing allegedly false information that misrepresented a drug’s end-of-shelf-life potency to extend its monopoly over the market for the mumps vaccine. AAI filed a brief in support of a petition for the court to review a Third Circuit decision in favor of Merck, arguing that it should resolve the split in favor of other circuits, and formally adopt a misrepresentation exception to Noerr-Pennington.See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.